ArticleFrontiers in public health2025
Survival time and influencing factors among people living with HIV in Guilin City, Guangxi, China: a retrospective cohort study (1996-2022).
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HIV-tuberculosis co-infection in Liangshan, a resource-limited region of Southwest China: trends and implications in the context of integrated prevention, 2019-2024.Infectious diseases of poverty · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite significant advances in antiretroviral therapy (ART), substantial disparities in survival outcomes among people living with HIV (PLWH) persist in resource-limited settings. However, in Guangxi, a region heavily affected by the HIV/AIDS epidemic in China, research on the survival time of PLWH and its associated factors remains limited. This study aims to investigate the survival time and its influencing factors among PLWH in Guilin, Guangxi, from 1996 to 2022, filling an important gap in regional HIV epidemiological research. Methods: A retrospective cohort study method was used to study PLWH whose current address was reported as local in Guilin from 1996 to 2022. The life table method and Kaplan-Meier method were used to calculate the survival rate and draw the survival curve, and the Cox proportional hazards regression model was used to analyze the influencing factors of the survival time of PLWH. Results: A total of 16,068 HIV/AIDS patients were included in the study, with a mortality rate of 8.67/100 person-years. The median survival time of PLWH was 14.11 years (95% CI: 13.50-15.70), and the 1-year, 3-year, 5-year, and 10-year cumulative survival rates were 72, 66, 62, and 54%, respectively. Cox proportional hazards model analysis identified factors significantly associated with increased risk of death, including male sex (HR = 1.425, 95% CI: 1.334-1.522), older age, low education level, unmarried status, farming occupation, and not receiving ART (HR = 10.578, 95% CI: 9.880-11.326). In contrast, individuals infected through heterosexual transmission and those identified through counseling and testing services had better survival outcomes. Lower CD4+T lymphocyte count at enrollment was associated with a higher risk of death. Conclusion: Survival time of PLWH is affected by many factors. In the context of the continuous improvement of policies and measures of Guilin City's anti-HIV attack project, behavioral interventions for key populations as well as publicity in rural areas should be strengthened, and early detection and treatment should be advocated in order to improve the quality of survival of PLWH and prolong their survival time. The findings of this study can provide scientific evidence for optimizing HIV prevention and control strategies in similar settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.